Citations

Clear

1828 citation(s) found for "Su, Emily".

Abstract 2319: Dynamics of TET methylcytosine dioxygenases in 5-methylcytosine and 5-hydroxymethylcytosine patterning in human cancer cells
Putiri, Emily, Tiedemann, Rochelle L. , Choi, Jeong‐Hyeon , Robertson, Keith D.

Mayo Clinic

Cancer Research | May 1, 2015 | Volume: 74 | Issue: 19_Supplement | Pages: 2319-2319

10.1158/1538-7445.am2014-2319 Get It

Abstract The Ten-eleven translocation (TET) family of dioxygenases hydroxylate 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC) in DNA. 5mC provides important epigenetic instructions during development, and its aberrant control is a major contributor to cellular transformation; however TET functions in regulating the epigenome, particularly in cancer, remain largely unknown. We targeted TET1, TET2, and TET3 for siRNA-mediated depletion in pluripotent human embryonic carcinoma cells and examined the impact on 5mC and 5hmC genome-wide localization. TET1, TET2, and TET3 co-regulate 5hmC at many sites, and depletion of only one of the TETs is sufficient to reduce 5hmC at these co-regulated sites, suggesting a functional co-dependence for TETs. Depletion of TET1 and TET2 had the greatest impact on 5hmC levels at high and low CpG density promoters, respectively, indicating that TETs exhibit DNA sequence-based functional specificity. All TETs prevent hypermethylation throughout the genome, especially in CpG island shores, where TET depletion resulted in prolific hypermethylation. Promoter hypermethylation resulting from TET depletion was associated with histone H2AK119 monoubiquitination, DNMT1, and DNMT3B occupancy. Surprisingly, TETs also promote cytosine methylation, as many loci became hypomethylated following TET depletion. Induction of differentiation generally caused 5hmC reduction, except at transcriptionally activated genes, which become enriched for 5hmC. Importantly, genes prone to promoter hypermethylation in cancer become depleted of intragenic 5hmC and 5mC with TET deficiency. This study highlights the multi-dimensional functions of TETs in mediating DNA methylation, hydroxymethylation, and gene expression patterns, and the results reveal that chromatin landscape and DNA sequence composition are regulators of TET function. Citation Format: Emily L. Putiri, Rochelle L. Tiedemann, Jeong-Hyeon Choi, Keith D. Robertson. Dynamics of TET methylcytosine dioxygenases in 5-methylcytosine and 5-hydroxymethylcytosine patterning in human cancer cells. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 2319. doi:10.1158/1538-7445.AM2014-2319
Abstract 1413: RUNX3 plays an oncogenic role in Ewing sarcoma cells
Bledsoe, Krista L., Oliveira, André M. , Wijnen, André J. van , McGee‐Lawrence, Meghan E. , Camilleri, Emily T. , Westendorf, Jennifer J. , van Wijnen, Andre J

Mayo Clinic

Cancer Research | May 1, 2015 | Volume: 74 | Issue: 19_Supplement | Pages: 1413-1413

10.1158/1538-7445.am2014-1413 Get It

Abstract Ewing sarcomas are aggressive, poorly differentiated pediatric tumors of bone and soft tissue. Ewing sarcoma affects one to three people per million every year and is the second most common pediatric bone malignancy after osteosarcoma. Approximately 85% of Ewing sarcomas harbor the EWS-FLI fusion protein, which arises from a chromosomal translocation, t(11:22)(q24:q12). EWS-FLI interacts with numerous lineage-essential transcription factors to maintain mesenchymal progenitors in an undifferentiated state. We previously showed that EWS-FLI binds the osteogenic transcription factor RUNX2, and prevents osteoblast differentiation. RUNX3 is highly homologous to RUNX2 and participates in the mesenchymal-derived bone formation. RUNX3 has been described as both a tumor suppressor and an oncogene in different tumor types. In this study, we investigated the role of RUNX3 in Ewing Sarcoma. RUNX3 was detected in all Ewing sarcoma cells examined (7/7 cell lines, and 4/4 primary tumors), whereas RUNX2 was detected in only 73% of these specimens. Immunoprecipitation experiments revealed that RUNX3 binds to EWS-FLI via its Runt domain, which is >91% identical to the Runt domain in RUNX2. The interaction between RUNX3 and EWS-FLI in cell nuclei was confirmed by immunofluorescence. Moreover, EWS-FLI interactions prevented RUNX3 from activating the transcription of a RUNX-responsive reporter, p6OSE2. To determine the role of RUNX3 in Ewing sarcoma cell growth, we stably suppressed RUNX3 expression in the Ewing sarcoma cell line A673 with shRNAs. In anchorage independent growth assays in soft agar, RUNX3-deficient A673 cells formed smaller colonies than cells expressing scrambled shRNAs. Consistent with the smaller colonies, RUNX3 suppressed cells had increased expression of the cyclin dependent kinase inhibitor p21. Taken together, these results suggest and oncogenic role for RUNX3 in Ewing sarcoma. Citation Format: Krista L. Bledsoe, Meghan E. McGee-Lawrence, Emily T. Camilleri, Andre M. Oliveira, Andre J. van Wijnen, Jennifer J. Westendorf. RUNX3 plays an oncogenic role in Ewing sarcoma cells. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 1413. doi:10.1158/1538-7445.AM2014-1413
Direct Detection of Influenza A and B Viruses in Less Than 20 Minutes Using a Commercially Available Rapid PCR Assay
Binnicker, Matthew J. , Espy, Mark J., Irish, Cole L., Vetter, Emily A.

Mayo Clinic

Journal of Clinical Microbiology | April 30, 2015 | Volume: 53 | Issue: 7 | Pages: 2353-2354

10.1128/jcm.00791-15 | PMID 25926484 Get It

ABSTRACT We compared an FDA-cleared rapid (<20 min) PCR assay (Cobas Liat; Roche Diagnostics) to our routine influenza A and B real-time PCR assay (Simplexa Flu A/B & RSV Direct; Focus Diagnostics) using respiratory swabs ( n = 197). The Cobas Liat influenza A and B assays demonstrated sensitivities of 99.2% (123/124) and 100% (23/23), respectively, while showing a specificity of 100% for each target.
Normal Villous Architecture With Increased Intraepithelial Lymphocytes
Patterson, Emily R., Shmidt, Eugenia , Smyrk, Thomas C. , Enders, Felicity T, Oxentenko, Amy S. , Enders, Felicity

Mayo Clinic

American Journal of Clinical Pathology | February 26, 2015 | Volume: 143 | Issue: 3 | Pages: 445-450

10.1309/ajcpbkqnd4shvx9q | PMID 25696804 Get It

Relationship between hippocampal atrophy and neuropathology markers: A 7T MRI validation study of the EADC‐ADNI Harmonized Hippocampal Segmentation Protocol
Apostolova, Liana G. , Zarow, Chris, Biado, Kristina, Hurtz, Sona, Boccardi, Marina , Honarpisheh, Hedieh, Blanken, Anna E., Brook, Jenny , Tung, Spencer, Kraft, Emily, Lo, D.C.W. , Ng, Denise , Alger, Jeffry R. , Vinters, Harry V. , Bocchetta, Martina , Duvernoy, Henri M., Jack, Clifford R. , Frisoni, Giovanni B. , Segmentation, EADC‐ADNI Working Group on the Harmonized Protocol for Manual Hippocampal, Bartzokis, George, Csernansky, John G., deToledo‐Morrell, Leyla, Lehéricy, Stéphane , Malykhin, Nikolai , Pantel, Johannes, Pruessner, Jens C. , Watson, Craig, Boccardi, Marina , Frisoni, Giovanni B. , Somme, Johanne Hatteland , Segmentation, EADC‐ADNI Working Group on the Harmonized Protocol for Manual Hippocampal, Leon, Mony J. de , Killiany, Ronald , Soininen, Hilkka S. , Jack, Clifford R , Bocchetta, Martina

Mayo Clinic

Alzheimer's & Dementia | January 22, 2015 | Volume: 11 | Issue: 2 | Pages: 139-150

10.1016/j.jalz.2015.01.001 | PMID 25620800 Get It

AbstractObjectiveThe pathologic validation of European Alzheimer's Disease Consortium Alzheimer’s Disease Neuroimaging Initiative Center Harmonized Hippocampal Segmentation Protocol (HarP).MethodsTemporal lobes of nine Alzheimer's disease (AD) and seven cognitively normal subjects were scanned post‐mortem at 7 Tesla. Hippocampal volumes were obtained with HarP. Six‐micrometer‐thick hippocampal slices were stained for amyloid beta (Aβ), tau, and cresyl violet. Hippocampal subfields were manually traced. Neuronal counts, Aβ, and tau burden for each hippocampal subfield were obtained.ResultsWe found significant correlations between hippocampal volume and Braak and Braak staging (ρ = −0.75, P = .001), tau (ρ = −0.53, P = .034), Aβ burden (ρ = −0.61, P = .012), and neuronal count (ρ = 0.77, P < .001). Exploratory subfield‐wise significant associations were found for Aβ in Cornu Ammonis (CA)1 (ρ = −0.58, P = .019) and subiculum (ρ = −0.75, P = .001), tau in CA2 (ρ = −0.59, P = .016), and CA3 (ρ = −0.5, P = .047), and neuronal count in CA1 (ρ = 0.55, P = .028), CA3 (ρ = 0.65, P = .006), and CA4 (ρ = 0.76, P = .001).ConclusionsThe observed associations provide pathological confirmation of hippocampal morphometry as a valid biomarker for AD and pathologic validation of HarP.
Triple modality testing by endoscopic retrograde cholangiopancreatography for the diagnosis of cholangiocarcinoma
Nanda, Arjun , Berger, Stephen, Lewis, Melinda M., Keilin, Steven , Woods, Kevin E. , Cai, Qiang , Willingham, Field F. , Barr Fritcher, Emily G, Brown, Jason , Fritcher, Emily G. Barr , Gores, Gregory J. , Willingham, Field F

Mayo Clinic

Therapeutic Advances in Gastroenterology | January 7, 2015 | Volume: 8 | Issue: 2 | Pages: 56-65

10.1177/1756283x14564674 | PMID 25729431 Get It

Objectives: Brush cytology has a low sensitivity for the diagnosis of cholangiocarcinoma. This study aimed to compare the standard approach (brush cytology) with a triple modality approach utilizing brush cytology, forceps biopsy and fluorescence in situ hybridization in terms of sensitivity and specificity for the diagnosis of cholangiocarcinoma. Methods: In a retrospective study at a single academic center, 50 patients underwent triple modality testing. Additionally, 61 patients underwent brush cytology alone. Intervention was endoscopic retrograde cholangiopancreatography with brush cytology, fluorescence in situ hybridization, and forceps biopsy. The main outcome measures included sensitivity, specificity, positive predictive value and negative predictive value. Results: Overall, 50 patients underwent triple tissue sampling, and 61 patients underwent brush cytology alone. Twenty-two patients were eventually diagnosed with cholangiocarcinoma. Brush cytology had a sensitivity of 42%, specificity of 100%, positive predictive value of 100% and negative predictive value of 88%. Triple tissue sampling had an overall sensitivity of 82%, specificity of 100%, positive predictive value of 100%, and negative predictive value of 87%. Within the triple test group, brush cytology had a sensitivity of 27%, forceps biopsy had a sensitivity of 50%, and fluorescence in situ hybridization analysis had a sensitivity of 59%. Conclusions: A triple modality approach results in a marked increase in sensitivity for the diagnosis of cholangiocarcinoma compared with single modality testing such as brush cytology and should be considered in the evaluation of indeterminate or suspicious biliary strictures.
Ventricular Conduction and Long-Term Heart Failure Outcomes and Mortality in African Americans
Mentz, Robert J. , DeVore, Adam D. , Choudhary, Gaurav , Ahmad, Tariq , Khazanie, Prateeti , Randolph, Tiffany C., Griswold, Michael , Eapen, Zubin J., O’Brien, Emily C. , Thomas, Kevin L. , Curtis, Lesley H. , Hernandez, Adrian F. , Greiner, Melissa A, Dunlay, Shannon M. , O'Brien, Emily C, Greiner, Melissa A. , Hernandez, Adrian , Mentz, Robert J

Mayo Clinic

Circulation: Heart Failure | December 31, 2014 | Volume: 8 | Issue: 2 | Pages: 243-251

10.1161/circheartfailure.114.001729 | PMID 25550439 Get It

Background— QRS prolongation is associated with adverse outcomes in mostly white populations, but its clinical significance is not well established for other groups. We investigated the association between QRS duration and mortality in African Americans. Methods and Results— We analyzed data from 5146 African Americans in the Jackson Heart Study stratified by QRS duration on baseline 12-lead ECG. We defined QRS prolongation as QRS≥100 ms. We assessed the association between QRS duration and all-cause mortality using Cox proportional hazards models and reported the cumulative incidence of heart failure hospitalization. We identified factors associated with the development of QRS prolongation in patients with normal baseline QRS. At baseline, 30% (n=1528) of participants had QRS prolongation. The cumulative incidences of mortality and heart failure hospitalization were greater with versus without baseline QRS prolongation: 12.6% (95% confidence interval [CI], 11.0–14.4) versus 7.1% (95% CI, 6.3–8.0) and 8.2% (95% CI, 6.9–9.7) versus 4.4% (95% CI, 3.7–5.1), respectively. After risk adjustment, QRS prolongation was associated with increased mortality (hazard ratio, 1.27; 95% CI, 1.03–1.56; P =0.02). There was a linear relationship between QRS duration and mortality (hazard ratio per 10 ms increase, 1.06; 95% CI, 1.01–1.12). Older age, male sex, prior myocardial infarction, lower ejection fraction, left ventricular hypertrophy, and left ventricular dilatation were associated with the development of QRS prolongation. Conclusions— QRS prolongation in African Americans was associated with increased mortality and heart failure hospitalization. Factors associated with developing QRS prolongation included age, male sex, prior myocardial infarction, and left ventricular structural abnormalities.
Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma
Gopal, Ajay K. , Chen, Robert , Smith, Scott E. , Ansell, Stephen M. , Rosenblatt, Joseph D. , Engert, Andreas , Larsen, Emily K., Chi, Xuedong, Sievers, Eric L. , Younes, Anas , Savage, Kerry J. , Connors, Joseph M. , Sievers, Eric L , Gopal, Ajay

Mayo Clinic

Blood | December 23, 2014 | Volume: 125 | Issue: 8 | Pages: 1236-1243

10.1182/blood-2014-08-595801 | PMID 25533035 Get It

Key PointsA total of 47% of patients who achieved CR on brentuximab vedotin remain progression-free after being followed a median of 53 months. Younger age, less functional impairment, and lower disease burden at baseline were associated with CR and prognostic for longer survival.
Inherited Mutations in 17 Breast Cancer Susceptibility Genes Among a Large Triple-Negative Breast Cancer Cohort Unselected for Family History of Breast Cancer
Hart, Steven N. , Sharma, Priyanka , Miron, Penelope , Olswold, Curtis, Slettedahl, Seth W. , Hallberg, Emily, Guidugli, Lucia, Davila, Jaime , Beckmann, Matthias W. , Janni, Wolfgang , Rack, Brigitte , Ekici, Arif B. , Slamon, Dennis J. , Konstantopoulou, Irene , Vratimos, Athanassios, Fountzilas, George , Pelttari, Liisa M. , Tapper, William , Durcan, Lorraine , Cross, Simon S. , Pilarski, Robert , Klemp, Jennifer R. , Cox, Angela , Brauch, Hiltrud , Yannoukakos, Drakoulis , Slager, Susan L., Vachon, Celine M. , Eccles, Diana M., Fasching, Peter A. , Eccles, Diana , Wang, Xianshu , Slettedahl, Seth, Davila, Jaime I, Tapper, William J, Shapiro, Charles L. , Klemp, Jennifer, Garber, Judy, Ambrosone, Christine, Couch, Fergus J. , Toland, Amanda Ewart , Olson, Janet E. , Godwin, Andrew K. , Pankratz, V. Shane , Fostira, Florentia , Yao, Song , Garber, Judy E. , Ambrosone, Christine B. , Nevanlinna, Heli , Vachon, Celine M. , Eccles, Diana M., Fasching, Peter A , Pelttari, L M , Eccles, Diana , Konstantopoulou, Irene , Slettedahl, Seth W , Hart, Steven N , Cox, Angela , Ekici, Arif B , Davila, Jaime I , Yannoukakos, Drakoulis , Sharma, Priyanka , Brauch, Hiltrud

Mayo Clinic

Journal of Clinical Oncology | December 2, 2014 | Volume: 33 | Issue: 4 | Pages: 304-311

10.1200/jco.2014.57.1414 | PMID 25452441 Get It

Purpose Recent advances in DNA sequencing have led to the development of breast cancer susceptibility gene panels for germline genetic testing of patients. We assessed the frequency of mutations in 17 predisposition genes, including BRCA1 and BRCA2, in a large cohort of patients with triple-negative breast cancer (TNBC) unselected for family history of breast or ovarian cancer to determine the utility of germline genetic testing for those with TNBC. Patients and Methods Patients with TNBC (N = 1,824) unselected for family history of breast or ovarian cancer were recruited through 12 studies, and germline DNA was sequenced to identify mutations. Results Deleterious mutations were identified in 14.6% of all patients. Of these, 11.2% had mutations in the BRCA1 (8.5%) and BRCA2 (2.7%) genes. Deleterious mutations in 15 other predisposition genes were detected in 3.7% of patients, with the majority observed in genes involved in homologous recombination, including PALB2 (1.2%) and BARD1, RAD51D, RAD51C, and BRIP1 (0.3% to 0.5%). Patients with TNBC with mutations were diagnosed at an earlier age (P < .001) and had higher-grade tumors (P = .01) than those without mutations. Conclusion Deleterious mutations in predisposition genes are present at high frequency in patients with TNBC unselected for family history of cancer. Mutation prevalence estimates suggest that patients with TNBC, regardless of age at diagnosis or family history of cancer, should be considered for germline genetic testing of BRCA1 and BRCA2. Although mutations in other predisposition genes are observed among patients with TNBC, better cancer risk estimates are needed before these mutations are used for clinical risk assessment in relatives.